Aligos Hosts KOL Event: ALG-055009 Phase 2a MASH Study on March 7

Aligos Therapeutics, a biopharmaceutical firm, is set to conduct a virtual event with a Key Opinion Leader (KOL) on March 7, 2024, to discuss metabolic dysfunction-associated steatohepatitis (MASH), previously referred to as NASH. The event will feature Dr. Stephen Harrison, a distinguished medical professional and Visiting Professor at the University of Oxford, who will delve into the current treatment landscape for MASH patients and the unmet needs within this area.

Dr. Harrison, who has an extensive background in hepatology, will also highlight the unique attributes of ALG-055009, a next-generation thyroid hormone beta agonist being developed by Aligos. The event will include a formal presentation followed by a live Q&A session, allowing attendees to engage directly with Dr. Harrison.

Dr. Harrison's credentials include being the Founder and Chairman of Pinnacle Clinical Research and Co-Founder and Chairman of Summit Clinical Research. He has a wealth of experience in the medical field, with a medical degree from the University of Mississippi School of Medicine and a distinguished career in the U.S. Army, where he served as a Colonel and held various high-ranking positions.

Aligos Therapeutics, founded in 2018, is dedicated to advancing treatments for liver and viral diseases. The company aims to leverage its team's expertise to discover and develop innovative therapies for MASH and other high-need diseases such as coronaviruses and chronic hepatitis B (CHB).

The company's mission is underscored by its commitment to addressing the significant unmet medical needs in the treatment of liver and viral diseases. With a focus on developing potentially best-in-class therapeutics, Aligos is poised to make a significant impact in the healthcare sector.